• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

otezla

  1. OX40

    Do we wait it out for OX40? Or is it time to jump ship now
    • anonymous
    • Thread
    • amgen dermatology otezla
    • Replies: 9
    • Forum: Amgen

  2. Amgen to take over Celgene’s OTEZLA for $13.4 billion; BMS increases share buyback

    Bristol-Myers-Squibb announced that Amgen will acquire Celgene’s Otezla business for $13.4 billion in a cash transaction. Bristol-Myers now expects to complete the pending merger with Celgene by the end of 2019. For More:
    • anonymous
    • Thread
    • amgen bristol-myers squibb celgene healthcare otezla pharma
    • Replies: 0
    • Forum: Bristol-Myers Squibb

  3. Celgene plunges to new 52-week low

    What's the reason for Celgene going down even after beating the estimates and lifting 2018 outlook? Any thoughts? https://news.alphastreet.com/celgene-celg-stock-q3-2018-earnings/
    • anonymous
    • Thread
    • bristol-myers squibb celgene earnings mark alles merck novartis otezla outlook pharma revlimid
    • Replies: 59
    • Forum: Celgene

  4. Celgene's 4th quarter 2017 sales and profit beat estimates

    http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and Juno) multi-billion dollar acquisitions help the struggling Celgene in 2018 and beyond?
    • anonymous
    • Thread
    • cancer cancer treatment celgene earnings juno therapeutics otezla outlook revlimid tax reform
    • Replies: 3
    • Forum: Celgene
Top Bottom
Back